Tag Archives: VBIV

VBI Vaccines (VBIV) Gets a Buy Rating from BMO Capital

In a report issued on June 25, Do Kim from BMO Capital maintained a Buy rating on VBI Vaccines (VBIV – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $3.10. According to TipRanks.com,

VBI Vaccines (VBIV) Initiated with a Buy at Canaccord Genuity

VBI Vaccines (VBIV – Research Report) received a Buy rating and a $4.00 price target from Canaccord Genuity analyst John Newman today. The company’s shares closed last Monday at $1.30. According to TipRanks.com, Newman is a 5-star analyst with an

VBI Vaccines (VBIV) Gets a Buy Rating from Oppenheimer

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on VBI Vaccines (VBIV – Research Report), with a price target of $9. The company’s shares opened today at $1.80. Gershell commented: “4Q18 net loss per share

VBI Vaccines (VBIV) Receives a New Rating from Oppenheimer

VBI Vaccines (VBIV – Research Report) received a Buy rating and a $9 price target from Oppenheimer analyst Leland Gershell today. The company’s shares closed yesterday at $1.77. Gershell noted: “We are initiating coverage on VBIV with an Outperform rating

Analysts’ Top Healthcare Picks: VBI Vaccines (VBIV), Endologix Inc (ELGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VBI Vaccines (VBIV – Research Report) and Endologix Inc (ELGX – Research Report) with bullish sentiments. VBI Vaccines (VBIV) In a report

Noble Financial Keeps a Buy Rating on VBI Vaccines

Noble Financial analyst Caroline Palomeque maintained a Buy rating on VBI Vaccines (NASDAQ: VBIV) yesterday. The company’s shares closed yesterday at $3.67. According to TipRanks.com, Palomeque is ranked 0 out of 5 stars with an average return of -16.7% and